Literature DB >> 31597018

Talking about Toxicity - "What We've Got Here Is a Failure to Communicate".

Chana A Sacks1, Pamela W Miller1, Dan L Longo1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31597018     DOI： 10.1056/NEJMp1908310

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences.

Authors:  Emily A Simons; Derek E Smith; Dexiang Gao; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2020-04-27       Impact factor: 15.609

2.  Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.

Authors:  Gita Thanarajasingam; John P Leonard; Thomas E Witzig; Thomas M Habermann; Kristie A Blum; Nancy L Bartlett; Christopher R Flowers; Brandelyn N Pitcher; Sin-Ho Jung; Pamela J Atherton; Angelina Tan; Paul J Novotny; Amylou C Dueck
Journal:  Lancet Haematol       Date:  2020-06       Impact factor: 18.959

3.  Asymmetric Reporting of Harms and Benefits in Randomized Controlled Trials.

Authors:  Rubaya Yeahia; Renee L Gennarelli; Daniel J Morgan; Deborah Korenstein
Journal:  J Gen Intern Med       Date:  2021-08-11       Impact factor: 6.473

4.  A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.

Authors:  Otto Metzger Filho; Anita Giobbie-Hurder; Nancy U Lin; Meredith Faggen; Steven Come; Thomas Openshaw; Michael Constantine; Jeanna Walsh; Rachel A Freedman; Bryan Schneider; Harold J Burstein; Erica L Mayer
Journal:  Breast Cancer Res Treat       Date:  2020-10-06       Impact factor: 4.872

Review 5.  Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.

Authors:  Rajshekhar Chakraborty; Brian T Hill; Aneela Majeed; Navneet S Majhail
Journal:  Transplant Cell Ther       Date:  2020-12-21

6.  Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer.

Authors:  Joshua Z Drago; Mithat Gönen; Gita Thanarajasingam; Chana A Sacks; Michael J Morris; Philip W Kantoff; Konrad H Stopsack
Journal:  J Natl Cancer Inst       Date:  2021-05-04       Impact factor: 13.506

7.  Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.

Authors:  Zachary W Veitch; Daniel Shepshelovich; Christina Gallagher; Lisa Wang; Albiruni R Abdul Razak; Anna Spreafico; Philippe L Bedard; Lillian L Siu; Lori Minasian; Aaron R Hansen
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506

8.  How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support.

Authors:  Maurice J Berkowitz; Carlie K Thompson; Laura T Zibecchi; Minna K Lee; Elani Streja; Jacob S Berkowitz; Cachet M Wenziger; Jennifer L Baker; Maggie L DiNome; Deanna J Attai
Journal:  J Cancer Surviv       Date:  2020-08-17       Impact factor: 4.062
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.